4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ovid Therapeutics Inc. (OVID) operates in the Biotechnology industry and is headquartered in New York, United States with about 23 employees. Its market capitalization is roughly $485 million. In the fiscal year ended 2025-12-31, OVID reported $7M in revenue and ($17M) in net income.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Interactive charts & full statements → Open the OVID valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $7M | $1M | $0M | $2M | — |
| Operating Income (EBIT) | ($42M) | ($62M) | ($59M) | ($56M) | — |
| Net Income | ($17M) | ($26M) | ($52M) | ($54M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $1M | $0M | $6M | $0M |
| Operating Income (EBIT) | ($18M) | ($12M) | ($12M) | ($5M) | ($13M) |
| Net Income | ($17M) | $10M | ($12M) | ($5M) | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $151M | $92M | $144M | $155M | — |
| Total Liabilities | $20M | $24M | $56M | $23M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OVID viewer.
About TickerBase · Data methodology & sources